News | October 08, 2014

Trial Results Show Enhanced Myocardial Recovery in Acute Myocardial Infarction Patients Treated With PICSO Impulse System

October 8, 2014 — Miracor Medical Systems announced that results from the prospective multicenter safety and feasibility study, ‘Prepare RAMSES,’ were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference last month in Washington, D.C., by co-investigator Tim P. van de Hoef, M.D., fellow of Jan Piek, M.D., Ph.D., principal investigator for the trial at Academic Medical Center, University of Amsterdam.

The ‘Prepare RAMSES’ study evaluated PICSO (pressure-controlled intermittent coronary sinus occlusion) as an adjuvant treatment in patients with acute ST-segment elevation myocardial infarction (STEMI) who were initially treated by primary percutaneous coronary intervention (PCI).

“Optimization of myocardial perfusion after PCI is considered an important therapeutic strategy to limit morbidity and mortality in patients with STEMI,” said van de Hoef. “We were able to confirm the safety of PICSO application in these patients, which is an important milestone toward addressing this large unmet clinical need.”

A secondary objective of the clinical study was to explore the magnitude of effect of PICSO on myocardial function and infarct size by magnetic resonance imaging (MRI) and compared with a historical control group. The study was able to demonstrate that successful administration of PICSO therapy was associated with up to 50 percent significantly greater myocardial recovery during four months follow-up when compared to the matched historical control patients.

“Myocardial perfusion remains impaired in up to 40 percent of patients with STEMI even after primary PCI, and this prevalence is associated with adverse clinical outcomes,” said Piek. “The clinical study showed that PICSO may significantly reduce infarct size and augment myocardial recovery after primary PCI in a dose-dependent manner.”

“The reduction of infarct size after myocardial infarction is a significant unmet clinical need and requires new therapeutic options for my daily clinical practice. I believe that U.S. cardiologists would embrace the PICSO technology as an adjunct to primary PCI,” said Thomas C. Piemonte, M.D., Lahey Hospital & Medical Center in Burlington, Mass.

The ‘Prepare RAMSES’ study additionally provided important user feedback that enabled Miracor to introduce a second-generation product portfolio and to redefine PICSO therapy based on the clinical results, allowing for patient treatment without significant prolongation of use of the cath lab, an important economic aspect of the PICSO Impulse system.

“The study results further encourage us in our efforts to reduce the negative long-term consequences of impaired cardiac function in patients after myocardial infarction,” said Ludwig Gold, CEO of Miracor Medical Systems. “Miracor has meanwhile made significant investments and recently launched the next generation of the PICSO Impulse system with substantial improvements to both the PICSO Impulse catheter and the PICSO Impulse console. We are now also able to more precisely define the necessary therapy and procedure to achieve significant clinical results. Successful usage in the United Kingdom and Hungary has shown significantly improved handling and stability of the systems, which will further increase the performance of the PICSO Impulse system.”

The Miracor PICSO Impulse system is designed to treat acute STEMI patients and less severe non-STEMI patients by improving myocardial perfusion in complement with PCI. The system is approved for sale in Europe; it is not approved for use in the United States.

For more information: www.miracormedical.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init